<DOC>
	<DOCNO>NCT00297882</DOCNO>
	<brief_summary>This proposal aim evaluate safety efficacy artemisinin-based anti-malaria combination drug ( ACTs ) treatment child age 1-10 year different location Cameroon . Randomized clinical trial provide local data safety test drug , putative marker mutation development resistance ACT . The study involve three centre , namely , Banso ( Guinea-Savannah region ) , Limbe ( Littoral Forest ) , Garoua ( Sahel-Savannah ) . The trial compare efficacy safety Amodiaquine ( AQ ) -Artesunate ( Art ) Coartem® ( Artemether-Lumefantrine ) . Drug efficacy determine use WHO standardise 28 day protocol . Safety monitor clinical examination , biochemical haematological index . Molecular marker artemisinin resistance investigate molecular sequence comparison parasite profile PfATP6 gene drug failure case , . Recrudescences re-infections assess analysis msp1 msp2 gene . The impact combination generation gametocyte determine gametocyte carriage rate measure microscopy .</brief_summary>
	<brief_title>Artemisinin-Based Combination Therapy : Clinical Trials Cameroon</brief_title>
	<detailed_description>- Out patient screen malaria blood film examination - Malaria-positive child examine physician inclusion exclusion ( see ) - Informed consent seek guardian potential patient - Patients guardian interview case record form complete - Patients randomise one two arm ratio 4:1 AQ/Art : CoArtem issue study card - Filter paper 5ml venous blood sample collect - Patients hospitalise three day allow completion therapy observation - The patient ask return day 7 , 14 28 assessment clearance recrudescence parasites - Patient examine parasite evaluate early treatment failure ( ETF ) , late treatment failure ( LTF ) , late parasitological failure ( LPF ) adequate clinical parasitological response. ( ACPR ) . - If patient appear follow , community health worker try trace collect blood onto filter paper microscope slide patient temperature ≥ 37.5°C - Patients whose parent opt study administer quinine sulphate parasitaemic - Filter paper sample air dry store dessicant require . - Whole blood sample collect citrate anticoagulant process plasma , aliquoted 300µl lot store -70°C . - Patient information enter close day laptops collectively send Yaounde end first month study thereafter end week , along hard copy case report form . - Analysis perform sample within three month collection molecular marker resistance , genetic structure parasites blood drug level medication use trial</detailed_description>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>Inclusion criterion : child age 110 year ; axillary temperature ≥ 37.5°C and/or history fever within past 24 hour ; P. falciparum asexual parasitaemia 1000 100000/µl ; ability attend followup visit . Exclusion criterion : coinfections ; underlie chronic disease ; severe malaria indicate hyperparasitaemia , severe anaemia ( PCV 15 % , Hb 5g/ml ) , respiratory distress , inability drink , persistent vomit past 24 hour ; recent history multiple convulsion ; jaundice ; inability stand sit ; history allergy study drug .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>120 Months</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Children</keyword>
	<keyword>Cameroon</keyword>
</DOC>